These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 11479542)

  • 21. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 22. Biotech financing retrenches in Q2.
    Lawrence S
    Nat Biotechnol; 2006 Aug; 24(8):883. PubMed ID: 16900116
    [No Abstract]   [Full Text] [Related]  

  • 23. The 802 million dollars fallacy.
    Hodgson J
    Nat Biotechnol; 2004 Sep; 22(9):1076. PubMed ID: 15340464
    [No Abstract]   [Full Text] [Related]  

  • 24. The European university as a startup generator.
    Witholt B
    Nat Biotechnol; 1999 Feb; 17 Suppl():BE7-8. PubMed ID: 10052313
    [No Abstract]   [Full Text] [Related]  

  • 25. Hedge funds gain edge by doubling biotech investments.
    Ransom J
    Nat Biotechnol; 2006 Apr; 24(4):373-4. PubMed ID: 16601707
    [No Abstract]   [Full Text] [Related]  

  • 26. Boutiques reborn in 2003.
    Surendran A
    Nat Biotechnol; 2004 Mar; 22(3):353-4. PubMed ID: 15017987
    [No Abstract]   [Full Text] [Related]  

  • 27. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 28. Financing falters, biotechnology shares deflate in 2001.
    Morrison C
    Nat Biotechnol; 2001 May; 19(5):393-4. PubMed ID: 11328980
    [No Abstract]   [Full Text] [Related]  

  • 29. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 30. Biotech holds steady in Q4.
    Mitchell P
    Nat Biotechnol; 2004 Feb; 22(2):135-6. PubMed ID: 14755275
    [No Abstract]   [Full Text] [Related]  

  • 31. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 32. Companies jostle for access to public markets.
    Bouchie A
    Nat Biotechnol; 2003 Dec; 21(12):1413-4. PubMed ID: 14647309
    [No Abstract]   [Full Text] [Related]  

  • 33. Biotech IPOs: handle with care.
    Jacobs T
    Nat Biotechnol; 2003 Dec; 21(12):1437. PubMed ID: 14647322
    [No Abstract]   [Full Text] [Related]  

  • 34. IPOs: the narrow window closes?
    Lawrence S
    Nat Biotechnol; 2004 Dec; 22(12):1489. PubMed ID: 15583641
    [No Abstract]   [Full Text] [Related]  

  • 35. Biotech IPOs--flop or pop?
    Jacobs T
    Nat Biotechnol; 2004 Aug; 22(8):949. PubMed ID: 15286641
    [No Abstract]   [Full Text] [Related]  

  • 36. Mind the (biomedical funding) gap.
    Klausner A
    Nat Biotechnol; 2005 Oct; 23(10):1217-8. PubMed ID: 16211055
    [No Abstract]   [Full Text] [Related]  

  • 37. France critiques its incubator before refinancing.
    Louët S
    Nat Biotechnol; 2004 Jan; 22(1):126. PubMed ID: 14725299
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech's perfect storm.
    Karberg S
    Cell; 2009 Aug; 138(3):413-5. PubMed ID: 19665960
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Biotech equities heat up in 1Q12.
    Yang W
    Nat Biotechnol; 2012 May; 30(5):384. PubMed ID: 22565955
    [No Abstract]   [Full Text] [Related]  

  • 40. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.